1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Asahi Kasei to Acquire Aicuris in €780 Million Deal, Expanding Push into Severe Infectious Diseases

27 Feb 2026
Admin
News Article

Asahi Kasei to Acquire Aicuris in €780 Million Deal, Expanding Push into Severe Infectious Diseases

Asahi Kasei has signed a definitive agreement to acquire all outstanding shares of Aicuris Anti-infective Cures AG for approximately €780 million (about $919 million).

The transaction is expected to close in the first quarter of fiscal 2026, subject to customary closing conditions. Asahi Kasei expects the acquisition to contribute positively to operating income from fiscal 2028 onward, after amortization of goodwill and intangible assets.

Strengthening a Focused Specialty Pharma Strategy

The acquisition aligns with Asahi Kasei’s strategy to build a sustainable, focused specialty pharmaceutical platform targeting immunocompromised and medically complex patients.

Severe infectious diseases are strategically adjacent to Asahi Kasei’s existing strengths:

Transplant medicine through its Veloxis business
Nephrology through Calliditas

In both areas, infection-related complications remain a major clinical challenge. By integrating Aicuris, Asahi Kasei plans to leverage:

Established commercial access to transplant centers and nephrology providers
Advanced R&D and regulatory capabilities
An existing specialty pharma infrastructure

This combination is expected to accelerate pipeline development while improving operating efficiency.

Strategic Fit With Long-Term Growth Targets

According to Asahi Kasei leadership, the deal supports the company’s broader pharmaceutical ambitions. The acquisition strengthens interconnected therapeutic areas:

Autoimmune diseases
Transplantation
Kidney disease
Severe infectious diseases

It also aligns with the company’s capital allocation framework and its goal of achieving ¥300 billion in pharmaceutical sales with an operating margin of 15% or higher by fiscal 2030.

Aicuris Portfolio Adds Near-, Mid-, and Long-Term Value

Aicuris brings a three-asset infectious disease portfolio that complements Asahi Kasei’s existing franchises.

1. CMV prevention in transplant recipients

Marketed product generating royalty income
Licensed to Merck & Co., Inc. (known as MSD outside the US and Canada)
Provides immediate, low-risk revenue contribution

2. Pritelivir for HSV in immunocompromised patients

Oral therapy with a novel mechanism of action
Phase III completed, with FDA approval targeted for 2026
Considered a key near-term value driver

This program fits well with Asahi Kasei’s strong presence in transplant centers and specialized hospital settings.

3. AIC468 for BK virus in kidney transplant patients

Antisense oligonucleotide targeting a major post-transplant complication
Phase I completed, with commercialization targeted around 2030
Strong overlap with Asahi Kasei’s renal and transplant networks

BK virus infection remains an area with limited approved treatment options, making this a strategically important long-term asset.

Layered Growth Profile Enhances Financial Durability

The acquisition creates a balanced growth trajectory:

Immediate royalties from the CMV franchise
Near-term commercial upside from pritelivir
Longer-term optionality from AIC468

Together, these assets are expected to support revenue durability, margin expansion, and earnings growth over time.

Part of a Broader Portfolio Transformation

This deal is one of several strategic moves reshaping Asahi Kasei into a more focused enterprise.

Under its medium-term plan, “Trailblaze Together,” Pharmaceuticals has been designated a First Priority business. The company continues to:

Reallocate capital toward high-growth healthcare areas
Simplify and optimize its portfolio
Transition toward a more capital-efficient structure

The Bigger Picture

With the acquisition of Aicuris, Asahi Kasei deepens its commitment to specialty pharmaceuticals and strengthens its position in severe infectious diseases—an area of growing importance as transplant medicine and immunosuppressive therapies expand globally.

If executed as planned, the deal positions Asahi Kasei for sustained growth across transplantation, nephrology, and infectious diseases over the next decade.